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336 The Journal of Thoracic and Cardbjective: Transannular patching of the right ventricular outflow tract results in
ulmonary insufficiency. Biologic monocusp valves prevent early pulmonary insuf-
ciency but usually become nonfunctional in less than 1 year. Polytetrafluoroeth-
lene monocusp leaflets demonstrated favorable characteristics in our animal studies
nd have been applied to a variety of right ventricular outflow tract reconstructions
t our institution.
ethods: From 1994 through 2006, 192 patients (mean age, 3.3  5.0 years)
nderwent right ventricular outflow tract reconstruction with a polytetrafluoroeth-
lene monocusp valve (192 patients; 202 implants). Intraoperative, early postoper-
tive, and late follow-up echocardiographic data (mean interval, 4.9  3.1 years;
ange, 6 months to 12 years) were retrospectively obtained to compare clinical
utcomes among three preoperative diagnostic groups: patients undergoing initial
epair of tetralogy of Fallot or pulmonary atresia/ventricular septal defect (group I),
atients undergoing redo right ventricular outflow tract procedures (group II), and
atients undergoing complex initial repairs (group III).
esults: There were 4 early and 5 late deaths (9/192; 5%). The difference between
he preoperative and postoperative peak right ventricular outflow tract gradients was
ignificant (71.2 vs 23.1; P  .0001). Twenty-five (14%) patients had mild-to-
oderate right ventricular outflow tract stenosis at one or more locations proximal
nd/or distal to the monocusp patch (mean gradient, 44.7  20.3 mm Hg). Freedom
rom increased pulmonary insufficiency greater than moderate was 86% at 1 year,
8% at 5 years, and 48% at 10 years. Twenty-five patients have undergone 35
eoperations 4.2  3.1 years (range, 3 months to 10 years after initial repair).
aplan–Meier freedom from reoperation was 96%, 89%, and 82% at 1, 5, and 10
ears. Freedom from reoperation in group II (69%) was significantly different from
roup I (88%; P  .01) and from group III (90%; P  .02), but there was no
ifference between groups I and III.
onclusions: Use of a polytetrafluoroethylene monocusp valve prevents early and
ignificantly reduces midterm pulmonary insufficiency. It is relatively inexpensive,
asy to construct, and remains free from significant stenosis in the majority of
atients. We have not witnessed significant calcification or pulmonary embolization,
nd the only antithrombic agent used has been low-dose aspirin.
he surgical management of patients with tetralogy of Fallot (TOF) and
significant right ventricular outflow tract (RVOT) obstruction at the valve
level, who are not candidates for a valve-sparing repair, has historically been
onducted in one of two ways: (1) transannular patch or (2) valved conduit insertion.
he advantages of a transannular patch are that it relieves right ventricular (RV)
ypertension immediately and the RVOT usually grows proportionally with the
iovascular Surgery ● May 2007
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Dhild. Reoperation for RVOT stenosis is generally uncom-
on. The disadvantage of the transannular patch is the
udden hemodynamic conversion of an obstructed, pressu
oaded RV to a volume-loaded RV, which causes temporary
nd/or delayed RV dysfunction. The chronic volume over-
oad of the RV and resultant ventricular dysfunction may
ecessitate late pulmonary valve insertion.1
The advantage of the valved conduit option is that it
ields initially a nearly competent pulmonary valve. Con-
uit insertion is particularly useful in patients who have
eripheral unrepaired pulmonary stenosis or elevated pul-
onary vascular resistance. The obvious disadvantages of
urrently available valved conduits are their lack of dura-
ility owing to shrinkage, lack of growth, and/or early
alvular dysfunction. These unsolved problems are mani-
ested by the allograft conduit that became popular in the
nited States during the mid-1980s. Pulmonary homografts
ave remained popular to the present despite freedom from
eoperation of only 50% at 5 years in patients undergoing a
on-Ross RVOT conduit repair.2,3
An attractive alternative strategy for many years has
een the creation of a monocusp RVOT patch, which has
he potential advantages and lacks the disadvantages of both
transannular patch and a homograft valve conduit in
ertain patient populations. The monocusp RVOT patch can
e created with autologous or bovine pericardium,4,5 allo-
raft pulmonary valve cusp,6 or the (off label) use of
olytetrafluoroethylene (PTFE) membrane (0.1-mm PTFE
atch; W. L. Gore & Associates, Inc, Flagstaff, Ariz) tra-
itionally used for pericardial closure.7-9 All types of mo-
ocusps have shown, particularly in the immediate postop-
rative period, to significantly reduce or prevent pulmonary
nsufficiency (PI).10
The elimination of PI is associated with faster recovery
f RV function, a lower central venous pressure, and less
ostoperative chest tube drainage.10 Construction of a per-
ardial or PTFE monocusp is simple, relatively inexpensive,
nd reproducible. Allograft pulmonary valve cusps are usu-
lly more expensive and more difficult to custom fit into the
VOT. The potential disadvantage of a monocusp patch in
omparison with insertion of a pulmonary valve or valved
Abbreviations and Acronyms
LV  left ventricle
PA  pulmonary artery
PI  pulmonary insufficiency
PTFE  polytetrafluoroethylene
RV  right ventricle(ular)
RVOT right ventricular outflow tract
TOF  tetralogy of Fallot
VSD  ventricular septal defectonduit is that, at least in some patients, PI recurs more o
The Journal of Thoracicuickly and completely if the monocusp sticks in the open
osition, as has been reported with biologic monocus6
ecurrent stenosis at the level of the monocusp is rarely
een with any monocusp RVOT patch.6,9
The goal of this retrospective review is to update our
revious experience with the PTFE monocusp patch9 and to
etermine its effects in relieving and preventing RVOT
tenosis and regurgitation in three groups of patients: pa-
ients undergoing initial repair of TOF or pulmonary atresia/
entricular septal defect (VSD) (group I), patients undergo-
ng redo-RVOT procedures (group II), and patients with
omplex initial RVOT reconstructions (group III).
atients and Methods
tudy Patients
ince 1994, 306 patients have undergone primary repair of TOF in
ur institutions: 46% of them underwent valve preservation sur-
ery (without any patching, only pulmonary artery [PA] augmen-
ation, only RVOT patch reconstruction, or both), 4% underwent
onduit insertion (patients with concomitant absent pulmonary
alve syndrome or patients with an important coronary artery
rossing the RVOT), and 50% underwent RVOT transannular
atching (93% of them with a PTFE monocusp). Between June
994 and April 2006, 192 patients with severe RVOT obstruction
nderwent reconstruction of the RVOT with a transannular patch
ith a PTFE monocusp valve at James Whitcomb Riley Hospital
or Children, Indianapolis, Indiana. One hundred seven (56%)
atients were girls and 85 (44%) were boys. Ages ranged from 6
ays to 35 years (mean, 3.3  5.0 years) and weights ranged from
.9 to 83 kg (mean, 14.0  14.2 kg).
The initial preoperative diagnoses and diagnostic groups they
ere assigned are shown in Table 1. Forty-six (24%) patient
ad prior cardiac operations, which included repair of the RVOT.
wenty-nine of these 46 patients had had RV-PA conduits before
mplantation of a PTFE monocusp valve, and they included pul-
onary homografts (n  15), aortic homografts (n  11), non-
alved Dacron tube graft (n  2), and Dacron graft with a porcine
alve (n  1). Six patients underwent initial transannular patching
ithout monocusp insertion.
Table 1 shows the characteristics of the three groups that 
ompared. Group I (n  121) was the infant or young child
ndergoing initial repair of TOF or VSD with pulmonary atresia.
roup II (n 35) was the older child who required reoperation for
ecurrent RVOT stenosis or regurgitation after initial repair with a
onvalved transannular patch or RV-PA conduit. Group III (n 
6) was a more varied and complex group undergoing initial repair
or TOF with absent pulmonary valve syndrome (n  6), TOF
r double-outlet right ventricle with atrioventricular septal de-
ect (n  7), TOF with discontinuous pulmonary arteries
n  3), double-outlet right ventricle (n  8), severe PI after
alloon pulmonary valvotomy (n  6), pulmonary stenosis after
rterial switch operation (n  4), PI after complete repair of
trioventricular septal defect (n  1), and initial truncus arte-
iosus repair (n  1). Three patients with pulmonary atresia and
SD underwent RVOT reconstruction without VSD closure
wing to hypoplastic PAs.
and Cardiovascular Surgery ● Volume 133, Number 5 1337
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DAll PTFE RVOT repairs were performed with a standard PTFE
onocusp valve construction technique as previously described.9,11
he monocusp valve is tailored and inserted first to get appropriate
idth and length. The outflow tract patch is then inserted with a
econd suture line. Assignment of patients to a particular surgeon
as random and without preference. Patients with defects that
ncluded an intact pulmonary annulus were evaluated in the oper-
ting room. When possible, an aggressive pulmonary valvotomy
as performed, the annulus was measured with a Hegar dilator,
nd the pulmonary valve was spared. In patients with moderate-
o-severe hypoplasia of the annulus (generally less than a 2
-value), a postrepair RVOT gradient measuring greater than 30
m Hg, or a postrepair RV pressure greater than 80% of systemic
ressure, a transannular repair was performed.5
After obtaining approval from our institutional review board,
e performed a retrospective review of medical records with
egard to initial cardiac diagnosis, pathophysiologic findings, sur-
ical treatment, and hospital mortality. Data from outpatient visits
nd from patients who died after hospital discharge were obtained
rom physicians, hospital records, or death certificates. Medical
ecords and clinical charts were reviewed for all PTFE monocusp
alve recipients including operative records as well as preoperative
nd postoperative catheterization and echocardiography data. Data
ollected from the operative admission included diagnosis, previ-
ABLE 1. Initial preoperative diagnosis
iagnosis
No. of
patients
roup I (n  121): Patients with initial repair of TOF,
PA/VSD
TOF 103
PA/VSD 18
roup II (n  35): Patients with redo RVOT
procedures
Truncus arteriosus 16
TOF 6
PA/VSD 6
DORV 5
s/p Ross procedure 2
roup III (n  36): Complex patients with initial
RVOT repair
DORV 8
TOF/AVSD 7
TOF/APVS 6
PI or PS, s/p balloon pulmonary valvotomy 6
D-TGA/Taussig-Bing anomaly, s/p switch operation 4
TOF/discontinuous pulmonary arteries 3
Truncus arteriosus 1
PI, s/p AVSD repair 1
otal 192
PVS, Absent pulmonary valve syndrome; AVSD, atrioventricular septal
efect; DORV, double-outlet right ventricle; D-TGA, dextro-transposition of
he great arteries; PA, pulmonary atresia; PI, pulmonary insufficiency; PS,
ulmonary stenosis; RVOT, right ventricular outflow tract; s/p, status post;
OF, tetralogy of Fallot; VSD, ventricular septal defect.us operative procedures, age, sex, and weight at operation. Patient o
338 The Journal of Thoracic and Cardiovascular Surgery ● Maollow-up data were obtained from hospital and clinic visit records.
ollow-up information was available within 2 calendar years for
6% of surviving patients. Echocardiography data, derived by
ontinuous-wave Doppler echocardiography, were recorded from
erial studies and used to quantitate postoperative PI. Evaluation of
he PTFE monocusp valve’s competency and relief of pulmonary
utflow tract obstruction included RV systolic pressure, RV-PA
radient, tricuspid regurgitation, and degree of PI. An end-diastolic
imension of the right and the left ventricles (RV and LV) by
ardiac magnetic resonance imaging has only recently become
vailable at our institution and was performed on selected patients.
chocardiographic assessment of the PTFE monocusp valve was
eported only for patients beyond 6 months after implant, and PI
as divided into three grades: trace-to-mild (trace, trace-to-mild,
ild), mild-to-moderate (regurgitation flow image confined within
he conduit), and moderate-to-severe (moderate, moderate-to-
evere, severe; regurgitation flow image extending into the sinus
ortions of the RV). In the same patient subset, Doppler interro-
ation was applied to detect the maximal flow velocity across the
VOT reconstruction. The pressure gradient was estimated by the
aximal flow velocity according to the Bernoulli equation.
tatistical Analysis
ariables including demographics, diagnosis, previous palliative
rocedures, types of previous RVOT reconstruction, conduit type
nd size, type of RVOT disease, need for postoperative extracor-
oreal membrane oxygenation, ratio between the end-diastolic
imensions of the RV and LV for selected patients, tricuspid
nsufficiency, RV pressure, and operative procedure-related vari-
bles were assessed by univariate analysis with the 2 test and
ultivariate logistic regression analysis. In the analysis of risk
actors for early death, variables with significant levels of 0.1 in
nivariate analysis were submitted to a multivariate logistic re-
ression model. Kaplan–Meier analysis was used for the actuarial
urvival and freedom from reoperation rate. Differences in survival
urves were assessed by log–rank test. All analyses were per-
ormed with SPSS statistical software (SPSS, Inc, Chicago, Ill).
arly mortality was defined as death during initial hospitalization
r within 30 days of operation. Any deaths later than that were
efined as late mortality. In this series, all early deaths occurred
uring the initial hospitalization and all late deaths occurred after
ischarge from the initial hospitalization.
esults
linical Outcomes
here were a total of 9 deaths (5%) with 4 early and 5 late
eaths. Three late deaths occurred during the first year after
he operation, one 2 years later, and one 8 years after the
nitial operation. The mean follow-up time is 4.9  3.1
ears (range, 6 months to 12 years). The mean intensive
are unit stay was 5.8 days and the length of hospital stay
as 9.1 days. Details of early and late deaths are shown in
able 2. Univariate and multivariate analysis demonstra
he diagnosis of TOF plus absent pulmonary valve (P .03)
nd the need for postoperative extracorporeal membrane
xygenation (P .002) as the two most sensitive predictors
f early mortality in patients with PTFE monocusp RVOT
y 2007
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Deconstruction. Overall survivals estimated by the Kaplan–
eier method including early mortality were 96% at 1 and
 years and 95% at 10 years (Figure 1). Overall surviv
roups I, II, and III at 10 years were 98%, 97%, and 88%,
espectively. Group III (complex initial repair) had a higher
ortality, which was significantly different from group I
P  .01) but not group II (P  .21).
Postoperative low cardiac output syndrome occurred in 6
atients (6/192; 3%) and all required postoperative extra-
orporeal membrane oxygenation. Two patients died (early
eath described above). The other 4 patients were success-
ully weaned from extracorporeal membrane oxygenation.
dditional morbidity included delayed sternal closure (9 days)
n 1 patient, pleural effusion in 1 patient, and complete heart
lock requiring pacemaker insertion in 4 patients.
eoperations
hirty-five reinterventions were required after PTFE mono-
usp RVOT reconstruction in 25 of 188 (13%) early survi-
ors. The monocusp was replaced with an RV-PA conduit
n 13), redo PTFE monocusp valve replacement (n 10),
urgical angioplasty of branch pulmonary stenosis (left or
ight) (n  6), stent placement (n  2), delayed VSD
losure (n  3), and RVOT patch augmentation below an
nomalous left anterior descending coronary artery (n  1).
ixteen, 8, and 1 patient have had 1, 2, or 3 reinterventions,
ABLE 2. Cause of early or late deaths (n  9)
o. Diagnosis Age Time of death Ca
1 TOF/PA 9 mo Late (3 mo) Pneu
2 TOF 14 mo Late (7 mo) Respi
3 TOF 9 mo Early (30 d) Sepsi
4 TOF/RVOT conduit 7 mo Late (2 y) Pneu
5 TOF/APV 6 d Early (29 d) LCO
6 TOF/APV 2 mo Early (5 d) LCO
7 TOF/RPA atresia 3 yrs Early (5 d) LCO
8 PA/IVS 5 mo Late (4 y) Nonc
9 TA 7 wk Late (1 y) Sepsi
PV, Absent pulmonary valve; B-K, Beckwith-Wiedelmann; IVS, intact
olytetrafluoroethylene; RPA, right pulmonary artery; RVOT, right ventricu
igure 1. Kaplan–Meier estimated 12-year survival, including
.ospital mortality.
The Journal of Thoracicin
espectively. The average time to reintervention after PTFE
onocusp placement was 4.2  3.1 years (range, 3 months
o 10 years). Mean age at reintervention was 8.0 6.5 years
range, 18 months to 28 years).
At reoperation, all patients had some degree of PTFE
onocusp regurgitation. It was graded as trace-to-mild in
0, mild-to-moderate in 9, and moderate-to-severe in 6
atients. Seventeen of the 25 patients reoperated on after
TFE monocusp insertion had a combination of residual
VOT obstruction and monocusp insufficiency. Residual
VOT stenosis was usually multilevel and was rarely at the
evel of the monocusp. It usually occurred in younger,
maller infants with a significant degree of RVOT hypopla-
ia at the time of initial repair. Eight patients had branch PA
tenosis and most had some degree of infundibular obstruc-
ion. The peak systolic gradient across the RVOT before
eintervention in the 25 patients undergoing reinterventions
f the PTFE monocusp was 44.7  20.3 mm Hg (range,
0-85 mm Hg), as measured by preoperative echocardiog-
aphy. At reoperation, 13 patients had their monocusp con-
erted to a biologic valved conduit and 10 had a larger
TFE monocusp outflow patch inserted. Replacement con-
uit types were as follows: bovine jugular vein conduit
Contegra; Medtronic, Inc, Minneapolis, Minn; n  8),
ulmonary homograft (CryoLife, Inc, Kennesaw, Ga; n 
), and a stentless porcine aortic root (Medtronic Freestyle;
edtronic, Inc; n  2). Eight patients underwent surgical
ngioplasty of the right and/or left PAs with PTFE patches
n  6) or stent placement (n  2) owing to branch PA
tenosis.
Eight of 26 patients had had a previous RVOT recon-
truction (before PTFE monocusp) (18%, 8/44 survivors)
nd 17 procedures were in patients without any operation
efore PTFE monocusp insertion (12%, 17/144 survivors;
 .08). Univariate and multivariate analysis showed the
iagnosis of TOF plus absent pulmonary valve (P  .005)
nd higher initial postoperative RV systolic pressure (P 
f death Genetic syndrome Relationship to PTFE monocusp
Yes (Down) No
y distress Yes (Down) No
No No
No No
No No
No No
No No
c Yes (B-K) No
Yes (DiGeorge) No
icular septum; LCO, low cardiac output; PA, pulmonary atresia; PTFE,
tflow tract; TA, truncus arteriosus; TOF, tetralogy of Fallot.use o
monia
rator
s
monia
ardia
s
ventr05) as the strongest predictors for reoperation. Kaplan–
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Deier freedom from reoperation after PTFE monocusp con-
truction was 96% at 1 year, 89% at 5 years, and 82% at 10
ears (Figure 2). Freedom from reoperation in groups 
nd III at 10 years was 88%, 69%, and 90%, respectively.
reedom from reoperation in group II was significantly
igher than in group I (P  .01) and group III (P  .02) but
as not different between groups I and III.
ate Echocardiographic Follow-up
he transthoracic echocardiographic studies obtained in the
ast follow-up (6 months) were collected on 180 patients.
f the patient had been reoperated on for symptomatic
VOT stenosis or regurgitation with RV dilatation, the last
chocardiogram performed before reoperation was taken
nto consideration. Echocardiographic studies before death
ere also included. One hundred eighty patients had an
chocardiogram after a mean follow-up of 4.9  3.1 years
range, 6 months to 12 years).
Ventricular dimensions were evaluated in the short axis
n 158 patients: the mean ratio between the end-diastolic
imensions of the LV and RV was 0.63  0.18. In patients
ith mild PI, this ratio was smaller than in those with
igure 2. Kaplan–Meier estimated 12-year freedom from re-
peration.Figure 3. Pulmonary insufficiency detect
340 The Journal of Thoracic and Cardiovascular Surgery ● Ma,
reater than moderate PI (0.60  0.14 vs 0.66  0.21; P 
07) but was not significant. Patients who underwent PTFE
onocusp reoperation had a larger ratio than the ones who
id not require reoperation (0.60  0.12 vs 0.76  0.29;
 .001). Excluding the patients who required reoperation,
here was no difference (65.3  8.7 vs 63.7  8.6) between
atients with trace-to-mild and greater than moderate PI at
ast follow-up.
The mean RV systolic pressure in all patients was 47.5
6.9 mm Hg. There was no difference between patients with
race-to-mild and greater than moderate PI at last follow-up
47.3  17.0 and 47.7  17.0), but there was a significant
ifference between patients who underwent redo surgery
nd all other patients without reoperation (71.3  18.5 vs
2.1  10.9; P  .0001).
The severity of PI was assessed by color Doppler in 180
atients at last follow-up. These results are illustrated in
igure 3. Ninety-four (52%) had trace-to-mild PI, 73 (4
ad mild-to-moderate PI, and 13 (7%) had moderate-to-
evere PI. On data obtained 1 year after PTFE monocusp
alve insertion, the trace-to-mild degree of PI was detected
n 60% of all patients, with moderate-to severe PI in only in
3%. However, progression of PI was observed at 4 to 5
ears with mild-to-moderate PI in 46% of all cases, which
ecreased to 35% at 7 years. The progression of PI to
oderate-to-severe PI increased from 15% to 37% at 7
ears’ follow-up. Significant tricuspid regurgitation devel-
ped in 6 (3%) patients. The echocardiographic analysis at
ast follow-up showed that freedom from increased PI
reater than moderate was 86% at 1 year, 68% at 5 years,
nd 48% at 10 years. Freedom from increased PI greater
han moderate was 53%, 41%, and 49% at 10 years, respec-
ively. There are no differences between all groups I, II, and III.
The overall peak systolic gradient across the RVOT
efore PTFE monocusp insertion was 71.2  21.6 mm Hg
range, 16-160 mm Hg) as measured by echocardiography,ed on follow-up echocardiography.
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Dnd at late follow-up it was 23.1  12.5 mm Hg (P 
0001). Twenty-five (14%) patients had more than mild-to-
oderate stenosis located distal to the monocusp (mean,
4.6  17.2 mm Hg). Eight of those patients have under-
one surgical angioplasty or stent placement of the distal
ranch PAs.
iscussion
he operative repair of congenital heart malformations in
hich the RVOT is severely narrowed often requires incis-
ng the annulus of a dysplastic valve and widening of the
nfundibulum and main PA with a transannular patch to
elieve RV pressure overload. Transannular patching, how-
ver, leads to marked pulmonary incompetence.12,13 PI,
hen severe and chronic or associated with distal residual
bstruction or elevated pulmonary vascular resistance, re-
ults in RV failure. Symptomatic RV failure may be delayed
or several years and contribute to deterioration in func-
ional status at late follow-up.14,15
Conventional techniques to reduce PI at the time of
nitial repair include bioprosthetic valve insertion, valved
onduit insertion, or the creation of a monocusp valve.
llograft conduits were the initial valved conduits used for
econstruction of the RVOT by European surgeons; how-
ver, early preservation techniques with antibiotics or irra-
iation sterilization were associated with early allograft
onduit valve failure.16 Porcine heterografts mounted i
acron conduits became available in 1970 in a variety of
izes and were widely used for complex reconstructions in
he United States17 before cryopreserved allograft condui
ecame available in the United States during the mid-1980s.
orcine valved Dacron conduits became obstructed with a
hick neointimal peel and the valves calcified within 3 to 5
ears, and most of the small-diameter conduits became
bstructed. Homann and associates18 reported that after 
eriod of 10 years, 30% of children initially receiving
llografts and 70% of patients receiving xenograft conduits
ad undergone replacement of their initial RV-PA conduits.
The search continues for an ideal RVOT extracardiac con-
uit. Several centers have advocated using a stented14,17,19,20
r nonstented porcine aortic or xenograft pericardial valve
ounted inside a pericardial or PTFE tube for patients older
han 10 years. We have used both techniques and have
ound them satisfactory in teenagers and adults. However,
he size and rigidity of the valve ring and frame with the
tented porcine or pericardial valve reduces the valve orifice
rea and increases the risk of transmitting sternal compres-
ion through the valved conduit to the left main and or left
nterior descending coronary artery. The stentless porcine
alve as advocated by Kanter and colleagues20 has a stif
ortic wall support and eliminates the prosthetic frame and
he concern of sternal compression. Absence of a stent
llows placement of a valve with a significantly larger valve f
The Journal of Thoracicrifice area. We have recently used several stentless porcine
oots (Freestyle; Medtronic, Inc) as an RV-PA conduit, and
hey have worked well in older children and adults. The
tentless aortic root in our opinion is too stiff and noncom-
liant for infants and younger children and the Freestyle
requently requires addition of a proximal hood to complete
he RV connection.
In 1993, Yamagishi and Kurosawa7 and Oku and co-
eagues8 independently introduced 0.1-mm PTFE perica-
ial membrane as a readily available material with good
haracteristics for monocusp valve construction and com-
ared it with other monocusp leaflet materials. Our animal
tudies suggested that 0.1-mm PTFE functioned as well as,
r better than, fresh or glutaraldehyde-treated pericardium21
nitial clinical application of this technique in patients with
OF resulted in improvement of perioperative RV function,
nd the technique rapidly gained favor.9 It has subsequently
een used in more than 200 patients with a wide range of
VOT obstructive and regurgitation defects but is espe-
ially valuable in the small infant undergoing primary
epair.
The PTFE monocusp with separate RVOT patch has
een very useful for our patients with TOF and its variants
ike VSD with pulmonary atresia who require a transannular
atch and in patients requiring a second RVOT procedure
fter a failed conduit reconstruction (29 patients in this
eport). The monocusp valve has functioned very well in
ost patients for the first 2 to 3 years and up to 10 years in
ome patients, and the monocusp has not produced recurrent
VOT obstruction. Function of the monocusp persists out
o 12 years, but some regurgitation develops as the RVOT
rows.5,9 We believe that the PTFE monocusp reconstr-
ion of a failed allograft conduit is preferable to using a
econd allograft conduit which, in several series, failed
aster that the first allograft.2,22 Although the monocusp
evelops some regurgitation over time, it is better than no
alve or a valve that will likely become obstructed, as is
een with allograft and xenograft valves in Dacron RV-PA
onduits.
Previous reports in the literature suggesting inconclusive
erioperative function and clinical benefit of a PTFE mo-
ocusp valve may reflect the challenges of freehand con-
truction or the material chosen for monocusp valve con-
truction. In our series, reconstruction of the RVOT with a
TFE monocusp valve has proven to be a simple and
eproducible technique demonstrating excellent early post-
perative function with minimal PI. In addition, our results
uggest a degree of early clinical benefit in patients in whom
PTFE monocusp valve was used when compared with
istoric transannular repairs without pulmonary valve re-
onstruction,9 particularly in those with TOF or VSD w
ulmonary atresia. The PTFE monocusp valve has also been
ound to retain a significant degree of competency at mid-
and Cardiovascular Surgery ● Volume 133, Number 5 1341
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Derm follow-up in the TOF group, as well as the group
ndergoing replacement of the previous RV-PA conduit. As
result, we have favored the PTFE monocusp in both these
atient groups. Growth of the RVOT or eventual fibrocol-
agenous incorporation of the PTFE leaflet may limit long-
erm function of the monocusp in some patients. The PTFE
onocusp valve can be expected to retain adequate function
n the early-to-mid postoperative period with the only anti-
oagulant being low-dose aspirin (80 mg per day).
The decision to insert a biologic valved conduit or upsize
he PTFE monocusp patch was left up to the individual
urgeon and depended on the availability of a suitable
onduit. When a pulmonary homograft conduit was the only
onduit available, we were more likely to up-size the RVOT
ith a second PTFE monocusp patch because we thought it
ould be more durable than the other available conduits at
hat time. With the introduction of the bovine jugular ve-
ous valved conduit (Contegra) in 2001 for clinical trial, we
ave selectively used the Contegra in some patients who
equire conduit revision or replacement to see whether the
egree of mid-to-late regurgitation is less with the Contegra
s compared with the monocusp valve outflow patch.23
The current study has the limitations of a retrospective
eview and has no concurrent control group. Furthermore,
agnetic resonance imaging and more refined 2-dimensional
nd even 3-dimensional echocardiographic studies would
ave provided additional valuable data regarding evaluation
f RV function and dimensions as well as the PTFE mono-
usp valve mechanics. Exercise testing and assessment of
olume of oxygen uptake would better evaluate the func-
ional benefits of this and other RVOT reconstruction tech-
iques. Nevertheless, PTFE monocusp valve reconstruction
f the RVOT is a safe, effective, and durable technique for
he mid term in the majority of patients and may delay or
bviate the need to insert a homograft or xenograft valve in
ate follow-up. Continued use and long-term follow-up in-
luding magnetic resonance imaging and exercise testing is
ecessary to further demonstrate the value of this technique.
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iscussion
r Gordon Cohen (Seattle, Wash). Dr Brown, congratulations on
n interesting study, and thank you for sharing your excellent
esults for this technique with us. The work you presented today
epresents just one of the many contributions that you and your
roup have made to our understanding of how to best reconstruct
he RVOT in a variety of different congenital defects. After re-
iewing your study, I have three questions for you.
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DFirst, in the patients who required more than one PTFE mono-
usp valve, what was the cause of failure and the median and mean
ime to replacement? In addition, how did you choose in this group
f patients whether they would have repeat PTFE monocusp valve
eplacement versus an RV-PA conduit?
Second, 15% of the patients had implantation of the PTFE
onocusp after RV-PA conduit. Oftentimes when homograft con-
uits fail, they exhibit shrinkage and calcification. Your own data
uggested that there was a mean gradient of 78 mm Hg in these
radients consistent with shrinkage, calcification, or outgrowth.
ow did you decide which patients with previous artery to PA
onduits would benefit from a PTFE monocusp valve in this
roup?
Third, in your slide listing indications for PTFE monocusp
edo, you listed 10 patients with trace-to-mild PI as the reason.
any of the valved conduits that we use have trace-to-mild PI
mmediately after they are placed and the chest is closed. Why
ould trace-to-mild PI of the PTFE monocusp or any other valve
ther than for the reason of infection ever be an indication for
edo?
Dr Brown. Thank you, Dr Cohen. Those are all excellent
uestions. To answer your first question, in patients who under-
ent more than one PTFE monocusp, the cause of failure in almost
ll situations, as pointed out in the curves, was PI. Only a handful
f patients had stenosis.
The second part of that is, how did you choose in which
atients you would repeat a PTFE monocusp and in which ones
ould you use a conduit? To answer that question, if they previ-
usly had a conduit, we were not going to put in a second
omograft conduit because we know a second homograft conduit
ails faster than the first one. Therefore, if a patient had a failed
onduit we would put in a PTFE monocusp and then roof that over
ith another PTFE patch. That is how we decided. However, after
001, when the Contegra conduit came along, we had a choice of
ither doing a PTFE monocusp reconstruction of that RVOT or
utting in a Contegra conduit. I have to admit our results with the
ontegra conduit look pretty promising thus far, and we are
eaning in that direction in those whose initial repairs have failed.
To answer your second question, in the 15% of patients who
ad PTFE monocusp after RVOT conduits, the answer is almost
he same. We continue to try to use the PTFE monocusp in patients
n whom it makes sense, but when we have a conduit now that is
s good as the Contegra conduit, we are inclined to use more
ontegras when a reoperation is necessary. We usually reserve the
TFE monocusp for primary repairs.
Finally, you are absolutely right about the patients with trace
I. That is never an indication for replacement of a conduit or a i
The Journal of Thoraciceconstruction of the RVOT. We just listed those in the slide.
hose were the few patients who had significant stenosis. They
lso had mild PI, but we listed those diagnoses separately. We did
ot reoperate on patients with trace PI because we know that
lmost all pulmonary valves, pulmonary conduits, have some
eakage early in the postoperative period.
DOCTOR. I would like your comment on a couple issues.
bviously, this is a big issue for congenital heart surgeons. We are
eplacing the RVOT weekly in our patients. The issue that I have
een, though, is that over the past few years our indications for
einterventions seemed to be changed. Can you comment about
hat over the time frame of your study?
Second, we are on the verge of these readily deployable per-
utaneous valve replacements that are probably going to be most
uccessful in the pulmonary outflow tract first before they are
eployed in other regions. Does that influence your current recon-
truction? In other words, if a 20-year-old patient is referred to
ou, what kind of valve replacement do you do so that he or she
an be set up for subsequent percutaneous valve replacements?
Dr Brown. Those are both excellent questions. First of all, the
ay we are deciding to intervene has to do with magnetic reso-
ance imaging. We are studying all of our patients who have
ilated RVs with magnetic resonance images, comparing the end-
iastolic volumes of the RV with the LV. Right now we are using
he Emory formula. If the RV volume is twice that of the LV, we
now it is time to intervene even though the patient is asymptom-
tic because atrial arrhythmias are likely to develop shortly after
hose ventricles begin to dilate more than that and significant
ricuspid insufficiency is likely to occur. We would like to try to
ntervene before they get those arrhythmias or the tricuspid valve
egins to fail. We are doing more RVOT reconstructions than we
ave ever done in the past and we, like you, are doing them
eekly.
Percutaneous pulmonary valves are available in Europe now.
ore than 110 have been used in London. Yes, we would prefer to
ut a nonstented valve in the pulmonary position initially because
hat will make it easier for a stent-deployed valve later on. We are
sing more stentless valves in the adult patient population. I think
here is a little caution here, though, that at least the Contegra
onduit is what they use for the stent-mounted valves for the
ulmonary position. At least there are some early data that suggest
hen those valves are mounted inside a stent they do not last
early as long as if they were surgically implanted. We are going
o have to watch that patient population very closely, because I
now that at least 10% of the stent-mounted valves have failed
ithin a 2-year period and we do not see that with a surgicallynserted Contegra valve. We will need a little more follow-up.
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